FDA approves Akynzeo for prevention of Nausea and Vomiting for Cancer Chemotherapy patients-Eisai
On 10 October 2014 the FDA revealed that it had approved Akynzeo (netupitant and palonosetron) from Eisai. The new combination is indicated to treat Nausea and Vomiting in those undergoing Cancer Chemotherapy and comprises palonosetron that was approved in 2008 to treat Nausea and Vomiting during the first 24 hours on the start of Cancer Chemotherapy and netupitant the latest drug that which prevents the Nausea and Vomiting during both the acute and delayed phase (from 25 to 120 hours) after the start of chemotherapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.